Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | CCR8 | P51685 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 4/20 | 0.35 |
| ▸ | NOS2 | P35228 | 4/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475483 | 0.80 | HPGD (0.42) | HPGDSMN1; SMN2AURKATTKAURKB | |
| SCHEMBL14853027 | 0.79 | HPGD (0.67) | HPGDSMN1; SMN2CCR1CCR5CCR8 | |
| SCHEMBL15483443 | 0.79 | CSNK2A1 (0.37) | HPGDSMN1; SMN2CCR1CCR5CCR8 | |
| SCHEMBL4541186 | 0.78 | HPGD (0.55) | HPGDSMN1; SMN2CCR1CCR5CCR8 | |
| SCHEMBL3562229 | 0.78 | LRRK2 (0.46) | HPGDSMN1; SMN2CCR1CCR5CCR8 | |
| SCHEMBL21563189 | 0.77 | CSNK2A1 (0.36) | HPGDSMN1; SMN2APLNRGAACSNK2A1 | |
| SCHEMBL6792963 | 0.77 | NOS3 (0.48) | AURKATTKAURKBINCENPCCR1 | |
| SCHEMBL25343385 | 0.77 | HPGD (0.40) | HPGDSMN1; SMN2AURKATTKAURKB | |
| SCHEMBL21598409 | 0.77 | HPGD (0.40) | HPGDSMN1; SMN2AURKATTKAURKB | |
| SCHEMBL2208595 | 0.77 | AURKA (0.43) | HPGDSMN1; SMN2AURKATTKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12139462-B2 | Pyridinone MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240294508-A1 | RIP1 MODULATORS INCLUDING AZETIDINE CYCLIC UREAS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-09-05 | — | — | US | disclosed |
| EP-4413985-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| EP-4367099-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4341247-A1 | RIP1 MODULATORS INCLUDING AZETIDINE CYCLIC UREAS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024059096-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-117651698-A | Pyridone MK2 inhibitors and uses thereof | 新特拉有限公司 | 2024-03-05 | — | — | CN | disclosed |
| WO-2013051639-A1 | PYRAZOLOQUINOLINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013014170-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB SCIENCE (FR) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014170-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB SCIENCE (FR) | 2013-01-31 | — | — | WO | disclosed |
| EP-1581221-B1 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-1581221-A4 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7109339-B2 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060089390-A1 | 3-benzoyl-2,4,5-substituted pyridine derivatives or salts thereof and bactericides containing the same | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1581221-A2 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004056324-A2 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139462-B2 | Pyridinone MK2 inhibitors and uses thereof | ENPP2, PLP2, PDXK | HPGD 358/4885SMN1; SMN2 2697/4885AURKA 660/4885 |
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR5A | HPGD 4054/4885SMN1; SMN2 3119/4885AURKA 4468/4885 |
| US-20240294508-A1 | RIP1 MODULATORS INCLUDING AZETIDINE CYCLIC UREAS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | HPGD 2251/4885SMN1; SMN2 2868/4885AURKA 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.